References
- Petz LD, Swisher SN, editors, Clinical Practice of Blood Transfusion, 3rd ed. Churchill Livingstone, New York, 1996.
- Page TC, Light WR, McKay CB, Hellums JD. Oxygen transport by erythrocyte/hemoglobin solution mixtures in an in vitro capillary as a model of hemoglobin-based oxygen carrier performance. Microvasc Res 1998; 55: 54–64.
- Light WR, Jacobs EE, Rentko VT, Gawryl MS, Hughes GS. Use of HBOC-201 as an oxygen therapeutic in the preclinical and clinical settings. In: Rudolph AS, Rabinovici R, Feuerstein GZ, editors. Red blood cell substitutes: Basic principles and clinical applications. New York: Marcel Dekker Inc; 1998 p. 421–436.
- Pearce LB, Gawryl MS. Overview of preclinical and clinical efficacy of Biopure's HBOCs. In: Chang TMS, editor. Blood substitutes: principles, methods, products and clinical trials. New York: Karger Landes Systems; 1998. p. 82–100.
- Hughes GS, Antal EJ, et al. Physiology and pharmacokinetics of a novel hemoglobin-based oxygen carrier in humans, Critical Care Medicine 1196: 24, 756–764.
- Page TC, Light WR, Hellums JD. Prediction of microcirculatory oxygen transport by erythrocyte/hemoglobin solution mixtures. Microvasc Res 1998; 56: 113–126.
- Standl T, Horn P, Wilhelm S, Greim C, Freitag M, Freitag U, et al. Bovine haemoglobin is more potent than autologous red blood cells in restoring muscular tissue oxygenation after profound isovolaemic haemodilution in dogs. Can J Anaesth 1996; 43(7):714–723.
- Biopure Corporation personal communications.
- Jahr JS. A novel blood substitute: Use of HBOC-201 to decrease the need for RBC's: Results of pivotal Phase III clinical trial in orthopedic surgery patients, Presented at the Society of Critical Care Medicine 31st Annual Congress, San Diego, Cal., January 2002.